649 POSTER Phase I trial of BB-10901 (huN901-DM1) given daily by IV infusion for three consecutive days every three weeks in patients with SCLC and other CD56-positive solid tumors

Autor:	F.V. Fosella, HS Xie, Ken Donaldson, Penella J. Woll, S. Zildjian, Paul Lorigan, S. Welch, M. O'Brien, R.J. Fram, Y. Clinch
Rok vydání:	2006
Předmět:	Cancer Research IV Infusion medicine.medical_specialty Oncology business.industry medicine Every Three Weeks HuN901-DM1 In patient business Surgery
Zdroj:	European Journal of Cancer Supplements. 4:195-196
ISSN:	1359-6349
DOI:	10.1016/s1359-6349(06)70654-1
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::03b82c0cc8664aa1973a5b156736cef7 https://doi.org/10.1016/s1359-6349(06)70654-1 Zobrazit plný text záznamu Full Text from ScienceDirect